Click here to read about a new book on the Nanobiotic treatment concept

        We got involved with EECP in August of '97.  Hundreds of patients, most "too far gone" for other revascularization techniques, have been treated, and most have done well.  However, for EECP to work well, we need a stable cardiac rhythm, the absence of uncontrolled heart failure, and a reasonably intact lower extremity vasculature.  If blood flow to the legs is seriously impaired, we can pump all we want, but we will not be able to generate a retrograde diastolic pressure wave, and coronary collateral generation will be inefficient.

        Unfortunately, half of the patients referred to us by other cardiologists have one of these three characteristics.  We can stabilize the cardiac rhythm with drugs, and heart failure can be improved medically, but if there is poor blood flow to the legs - well, then we're stuck.  We can try as hard as we can and the patient can try as hard as he/she can, but these patients don't get a good result.  This is upsetting to all, as to these patients, EECP was their "last hope".

        Casting about for ways to help these people, looking for ways of improving lower extremity blood flow such that EECP would be possible, I came across the Nanobacterium sanguineum hypothesis in late May of '01.  This concept, originating from two Finnish scientists, is that calcific atherosclerosis, the stuff that is plugging up our arteries, is the result of long-standing infection with a bacteria that we can treat.  The microbiology of the offending organism, Nanobacterium sanguineum, as well as the results of an anti-Nanobacterial treatment study, were presented at the International Nanobacterial Symposium, conducted at the University of Kuopio, Finland, in March '01, and in the US at the International College of Integrative Medicine spring '01 meeting. 

        Initially I got a good laugh at the Finnish researchers' expense - what a ridiculous theory.  I "knew" that atherosclerosis was due to high cholesterol and the other risk factors that "we" knew about.  But the N. sanguineum concept could be backed up - 90 patients had been treated for N. sanguineum vascular wall infection and their CT coronary artery calcium scores had fallen (this was not felt to be possible in May of '01).  Then I recalled getting a good laugh 20 years ago when a medical researcher in Australia proposed that peptic ulcer disease was due to a bacterial infection.  Back then, we "knew" that ulcers were due to too much stomach acid.  We would give you acid suppressing drugs and when that didn't work we would operate.  Now we treat ulcers with antibiotics and ulcer surgery is a thing of the past.  I stopped laughing and started thinking.  MJ (see Case Studies - NB) had just been referred to us; three out of four of the bypass grafts placed six months earlier had closed down.  MJ was experiencing up to ten episodes of angina a day and really needed EECP - but he had an unstable heart rhythm and no pulses in his feet, and thus EECP alone was not going to get the job done.

        Given that MJ had no other option, I decided to treat him with the Nanobiotic (anti-Nanobacterial treatment regimen, developed by NanobacLabs).  You can review MJ's story in the Case Studies section, but suffice to say, MJ's CT calcium score dropped by 2000 points and his angina improved markedly.  Pulses developed in his feet, allowing us to treat him with EECP - MJ is now nearly angina free.  MP, a woman with occluded bypass grafts and advanced narrowings in the arteries serving her brain, kidneys, and legs, was our second patients to undergo EECP following Nanobiotic pre-treatment, and she got better.

        MJ, MP, and many other "too far gone for anything else" patients got better with Nanobiotic treatment.  The next step was to treat patients who were not yet "too far gone" -  they got better too.  Their symptoms, as a rule, improved.  Often, but not always, their CT coronary calcium scores dropped.  One good patient outcome led to another, and I am now a confirmed believer of the "Infection and Inflammation Hypothesis".  I feel that vascular wall infection with Nanobacterium sanguineum and other organisms, as well as immune system activation related to infection, is playing a critical, causative role in the development of calcific atherosclerosis, and I view Nanobiotic therapy as a  weapon against calcific cardiovascular disease.  At this point, I have started over 350 patients on Nanobiotic therapy, and I had the privilege of giving a talk on Nanobacterium sanguineum and Nanobiotic therapy at the spring '02 International College of Integrative Medicine (ICIM) and American College for Advancement in Medicine (ACAM) meetings, and to present a scientific update at the spring '04 ICIM meeting ( the Scientific Review section is essentially the handout constructed for these talks).  At this meeting I had the opportunity to speak with Nobel Prize nominee Neva Ciftcioglu PhD, the Finnish researcher who first isolated Nanobacterium sanguineum.  This concept will be refined as we learn more about infection and inflammation, and how they cause vascular disease, but this concept is going to change the way we practice cardiovascular medicine.  It is going to save millions of lives and billions of dollars.  I'm grateful that I can use this knowledge to help my patients now. 

        I will go into more detail in the Case Studies - NB section, but I am seeing symptomatic improvement, often striking, in the vast majority of the symptomatic patients who I have treated with Nanobiotic therapy.  This improvement is occurring in patients with new onset coronary symptoms, and in patients who are "too far gone" for any other standard or alternative therapies.  With Nanobiotic therapy, we typically see, and now expect to see, a:

©  Decrease or resolution of angina, even in patients with closed bypass grafts or restenosis following angioplasty or stent placement

©  Reduction in the UltraFast CT coronary artery calcium score - Approximately 50% of my patients experienced a >10% reversal

©  Increased exercise capacity, mirrored by improved stress EKG and stress echo findings

©  HDL cholesterol rises by 5-10 points; LDL cholesterol sometimes falls

©  Cardiac CRP, a marker of vascular wall inflammation, often falls

©  Peripheral and cerebral blood flow improves; bruits (whistles over the arteries that signify a narrowing) often resolve and non-invasive blood flow studies have improved

©  Abnormal heart pumping function and filling characteristics may improve

©  Elevated blood pressure often falls and medication requirements may decrease

    The content of the Nanobacterium sanguineum portion of the heartfixer.com website comes from my own experience with Nanobiotic therapy, what I have learned from the researchers and clinicians cited above, and from my own review of the research available to date.  Please look through this information and think it overt.  The Literature Review section is written for health care providers, and is a little technical; the other sections are written in more patient friendly terms.  NanobacLabs' website, nanobaclabs.com, presents an analysis of the scientific literature, and is written in patient friendly terms.  Dr. Ciftcioglu's website, nanobac.com., provides a comprehensive overview of Nanobacterial science.  The Nanonews & Dissent section directs you to newsletter and E-magazine articles on Nanobacterium sanguineum, including an excerpt from the June '02 issue of The Sinatra Health Report, cardiologist Stephen Sinatra's monthly newsletter (he cites our work, using NanobacTX as a "stepping-stone" to EECP).  Not everyone believes in the concept of Nanobiotic therapy, and I must tell you, not every one of my patients has responded favorably (there are no universal cures).  Some authorities, including clinicians and scientists who I know a little, or respect a lot by reputation, don't even believe that Nanobacterium sanguineum exists.  I do believe that N. sanguineum exists, and I've seen hundred of patients improve while on Nanobiotic therapy, but I don't believe that this organism is the only cause of atherosclerosis, nor that Nanobiotic therapy, as we know it now, is the be-all-and-end-all of cardiovascular disease treatments.  If we are to move forward in science, we need to look at all sides of the story, so in the Nanonews & Dissent   section I have included position papers written by individuals who feel that N. sanguineum does not exist.  This section contains a dissenting position paper written by Dr. Elmer Cranton, a clinician with expertise in the IV administration of EDTA, a rebuttal written by Dr. Oli Kajander, the co-discoverer of N. sanguineum, and Dr. Cranton's response, along with a position paper authored by Professor Charles Bryce, a Scottish researcher.  Patients, who simply want to get better, may skip the science if they wish and go straight to the Case Studies section, to see just what is possible with this approach, alone or in combination with EECP.  An exciting new book examines Nanobiotic therapy, and if you are interested in Nanobiotic therapy and the concepts behind it, I suggest you read this independently written work (which incidentally, has some nice things to say about me).  In The Calcium Bomb:  The Nanobacteria Link to Heart Disease and Cancer, scientific writers Douglas Mulhall and Katja Hansen give a clear, plain language explanation of how Nanobacteria were discovered, what role they play in disease, and the development of the Nanobiotic treatment regimen.  Click here for more information.  This is a worthwhile read.  I sincerely hope that this information is of value to you.   

                                                                                                                                                                      James C. Roberts MD FACC

                                                                                                                                                                                     last updated 6/26/04